Why Is Melatonin No Longer Recommended?

Melatonin use among U.S. adults more than quintupled between 1999 and 2018, yet now headlines ask whether it should be avoided. A 2023 JAMA study found that 88% of melatonin gummy products were inaccurately labelled, with some containing nearly 3.5 times the stated dose. The concern is real — but it targets a specific problem with how melatonin is formulated and dosed, not with the molecule itself. This article explains what the evidence actually shows, why standard products fall short, and what a well-designed melatonin supplement looks like.

Table of Contents

1. What Actually Changed: The Headlines vs. The Evidence
2. The Labelling Problem: You Don't Know What You're Taking
3. The Dosing Problem: Most OTC Products Are Dramatically Oversized
4. The Absorption Problem: Most of Your Tablet Never Reaches Your Brain
5. What the Evidence Shows: Melatonin Does Work — Within Limits
6. Precise Dosing by Design: The Liposomal Approach
7. Frequently Asked Questions
8. Conclusion

1. What Actually Changed: The Headlines vs. The Evidence

Melatonin has not been banned, recalled, or formally contraindicated by any major health authority for healthy adults. What changed is a convergence of three things: a JAMA study exposing widespread mislabelling in gummy products, a CDC report documenting 11,000 pediatric emergency department visits linked to unsupervised melatonin ingestion between 2019 and 2022, and growing concern that most people are taking doses 5 to 10 times higher than what research supports. The headlines compressed all of this into "melatonin is no longer recommended," which is a significant distortion.

The NIH's National Center for Complementary and Integrative Health states that short-term melatonin use appears safe for most adults. The American Academy of Sleep Medicine and American College of Physicians have noted insufficient evidence for chronic insomnia specifically — not a prohibition. The practical translation: melatonin used short-term, at low doses, in accurately labelled products, has a well-established safety and efficacy record. The problems are in the products, not the hormone.

The JAMA usage trend study from Mayo Clinic researchers tracked more than 55,000 adults and found that high-dose melatonin use (above 5mg per day) more than tripled between 2005 and 2018. That trend — more people taking higher doses from products of uncertain accuracy — is the safety story. It is also exactly what a precision, low-dose, third-party-tested product is designed to address.

2. The Labelling Problem: You Don't Know What You're Taking

The 2023 JAMA study tested 25 melatonin gummy products listed in the NIH's Dietary Supplement Label Database. Only 3 of the 25 products (12%) contained melatonin within 10% of the declared quantity. The remaining 22 ranged from 74% to 347% of the labelled dose. One product contained no detectable melatonin at all. Five products that declared CBD as an ingredient contained 104% to 118% more CBD than labelled — a substance the FDA currently prohibits from being marketed as a dietary supplement.

This is not a new finding. A 2017 Canadian study of 16 melatonin brands — covering liquids, capsules, tablets, and gummies — found that actual melatonin content ranged from 17% to 478% of the labelled quantity. The most extreme deviation (478%) came from the chewable category. These numbers describe the environment in which most people are currently taking melatonin: a market where the dose on the label and the dose in the product have no legally enforced relationship.

Because melatonin is classified as a dietary supplement in the U.S. rather than a pharmaceutical, the FDA does not require manufacturers to prove the accuracy of their label claims before going to market. This regulatory gap is the structural cause of the mislabelling problem. For consumers, the practical implication is that without a third-party-verified product, you have no reliable way to know what dose you're actually taking.

3. The Dosing Problem: Most OTC Products Are Dramatically Oversized

Your body produces between 0.1mg and 0.9mg of melatonin naturally at peak nighttime production. The most common OTC melatonin tablets and gummies contain 5mg, 10mg, or even 20mg per dose — between 10 and 200 times the body's natural output. The Sleep Foundation notes that studies show doses as low as 0.5–1mg can be just as effective as higher doses for many people, and that dosages above 5mg appear no more effective than those below.

• Body's natural nightly melatonin production: 0.1–0.9mg
• Evidence-supported effective dose range: 0.5–3mg
• Most common OTC tablet dose: 5–10mg
• Reported worst-case gummy content: up to 347% of label (potentially 17mg+ in a "5mg" gummy)

GoodRx's clinical review cites research showing that a 3mg dose produced similar sleep improvements to lower doses — but with higher rates of side effects, including hypothermia and a "hangover effect" from elevated melatonin persisting into the next day. Higher doses do not produce proportionally better sleep; they produce more side effects. The overconsumption problem is compounded when the product is also mislabelled upward.

A 2024 dose-response meta-analysis published in the Journal of Pineal Research analysed 26 randomised controlled trials involving 1,689 observations. Researchers found that melatonin efficacy for reducing sleep onset latency peaked at approximately 4mg/day — and that taking it 2–3 hours before your target bedtime outperformed the standard advice of 30 minutes. The takeaway: timing and dose precision matter more than taking as much as possible.

4. The Absorption Problem: Most of Your Tablet Never Reaches Your Brain

Standard oral melatonin tablets have an absolute bioavailability of approximately 15–20%. This means that if you take a 5mg tablet, roughly 0.75–1mg actually enters your bloodstream — the rest is metabolised by the liver during first-pass processing before it ever reaches circulation. This is a pharmacological reality for melatonin in all standard oral forms: capsules, tablets, and gummies.

The absorption gap creates a paradox. Manufacturers, aware that bioavailability is low, compensate by increasing the labelled dose. This produces products containing 5–10mg when 0.5–1mg of bioavailable melatonin would be sufficient. The problem is compounded when those high-dose products are also mislabelled upward: a "5mg" gummy containing 347% of its stated dose delivers the equivalent of a 17mg tablet, of which roughly 2.5–3.5mg reaches the bloodstream — potentially 5 to 7 times more than a well-designed low-dose supplement would deliver.

Liposomal delivery addresses this directly. Liposomes are phospholipid spheres — the same material as cell membranes — that encapsulate the melatonin and protect it through the digestive process. Liposomal melatonin achieves an estimated bioavailability of 80–95%, compared to 15–20% for standard tablets. This means a 1.5mg liposomal dose can deliver more melatonin to the bloodstream than a 5mg standard tablet — at a fraction of the intake. Onset is also faster: 15–30 minutes for liposomal formats vs. 60–90 minutes for swallowed tablets.

5. What the Evidence Shows: Melatonin Does Work — Within Limits

A meta-analysis of 19 randomised controlled trials involving 1,683 participants found that melatonin significantly reduced sleep onset latency by 7.06 minutes and increased total sleep time by 8.25 minutes compared to placebo. Critically, the effects did not dissipate with continued use — an important distinction from pharmaceutical sleep aids, which often lose efficacy over time. The authors noted that melatonin's absolute benefit is smaller than prescription insomnia drugs, but its side-effect profile is substantially more favourable.

The most common adverse effects in randomised placebo-controlled trials are minor: daytime sleepiness occurs in approximately 1.66% of participants, headache in 0.74%, and dizziness in 0.74%. A 2023 clinical review of melatonin safety in older adults confirmed that melatonin does not cause physical dependence, withdrawal symptoms, or rebound insomnia — three of the most significant risks associated with benzodiazepines and Z-drugs used for sleep.

Where the evidence is genuinely limited is long-term safety. The majority of melatonin trials run for fewer than 12 weeks, so there is no robust prospective data on nightly use over years. The NIH explicitly flags this gap — not as evidence of harm, but as an absence of evidence. For adults using melatonin short-term (1–2 months) at low, accurately dosed amounts, the risk-benefit calculation is favourable. The concerns that drove recent headlines apply most directly to high-dose, mislabelled gummy products used chronically — not to precision-dosed, third-party-tested supplements.

6. Precise Dosing by Design: The Liposomal Approach

The problems driving melatonin's safety debate — inaccurate labelling, oversized doses, poor absorption — are not inherent to melatonin. They are inherent to the most common product formats: high-dose gummies and tablets that are neither third-party verified nor designed for bioavailability. BioAbsorb Liposomal Liquid Melatonin was built around the three principles the research supports: low dose, high absorption, verified accuracy.

At $29.99 for 100ml (100 servings), each full dropper delivers 1.5mg of melatonin — already at the lower end of the evidence-supported range, and well within what liposomal bioavailability makes effective. The graduated dropper allows dose increments of approximately 0.25mg, which means you can start at 0.5mg, find your minimum effective dose over 3–4 nights, and adjust without splitting tablets or guessing. This is the dosing approach the Journal of Pineal Research meta-analysis and Sleep Foundation both advocate — start low, titrate up — made practically achievable.

BioAbsorb manufactures in a GMP-certified, Health Canada–approved facility in Canada. Every batch is third-party tested, with a Certificate of Analysis available on request — the verification mechanism that eliminates the labelling accuracy problem the JAMA study identified. The formulation is non-GMO, vegan, gluten-free, and free of artificial flavours or colours. If the melatonin debate is ultimately about not knowing what you're taking and taking too much of it, liposomal liquid with third-party verification and a graduated dropper is a direct structural response to both problems.

Frequently Asked Questions

Is melatonin actually banned or contraindicated?

No. No major health authority — the FDA, Health Canada, NIH, or CDC — has banned or formally contraindicated melatonin for healthy adults. The NIH states that short-term melatonin use appears safe for most people. The "no longer recommended" framing comes from concerns about specific product formats (high-dose gummies with inaccurate labels) and specific populations (children under unsupervised conditions), not a withdrawal of the supplement from adult use.

Why do so many melatonin products contain 5mg or 10mg if the effective dose is 0.5mg?

Standard oral tablets have a bioavailability of only 15–20%, so manufacturers increase the labelled dose to compensate. A 5mg tablet delivers roughly 0.75–1mg to the bloodstream. The problem is that this assumption compounds with mislabelling: a "5mg" gummy containing 347% of its stated dose effectively delivers 17mg, of which 2.5–3.4mg reaches circulation — 3 to 5 times a physiologically appropriate amount. Liposomal delivery solves this by raising bioavailability to 80–95%, so a lower labelled dose is both sufficient and accurate.

Can I become dependent on melatonin?

Physical dependence — the kind associated with prescription sleep aids like benzodiazepines — has not been reported with melatonin in clinical trials. The Sleep Foundation confirms that melatonin does not cause withdrawal symptoms or rebound insomnia upon stopping. That said, nightly melatonin use over long periods (beyond 1–2 months) lacks long-term safety data, and the NIH flags this gap. Short-term use at low doses is considered appropriate; chronic nightly use at high doses carries more uncertainty.

Why are melatonin gummies specifically a problem?

The CDC found that many of the approximately 11,000 pediatric ER visits between 2019–2022 involved flavoured gummy formulations — their child-friendly appearance and candy-like taste make accidental ingestion more likely, and their high doses (often 5–10mg per piece, sometimes mislabelled higher) make ingestion of multiple pieces a genuine risk. For adults, the gummy format has additional problems: it is the category with the worst labelling accuracy record, and it doesn't allow dose adjustments the way a liquid dropper does.

What is the right melatonin dose for an adult?

The research supports starting at 0.5–1mg, taken 1–2 hours before your intended sleep time. The body naturally produces only 0.1–0.9mg at peak nighttime levels, so even 1mg represents a meaningful supplement. Most adults achieve good results between 1–3mg; doses above 5mg are rarely necessary and increase side-effect risk without proportional sleep benefit. A 2024 dose-response meta-analysis in the Journal of Pineal Research found that timing — 2–3 hours before bed rather than 30 minutes — is as important as dose in determining effectiveness.

Is melatonin safe for long-term use?

The honest answer is that data is limited. Most clinical trials run fewer than 12 weeks, so long-term safety at nightly doses has not been formally established. Short-term use (1–2 months) at low to moderate doses (under 5mg) appears safe and well-tolerated based on available evidence. A 2025 American Heart Association preliminary study finding an association between long-term melatonin use and heart failure risk has not yet been published in a peer-reviewed journal and cannot confirm causation — but it adds reason for caution about chronic, high-dose use beyond what is needed.

Conclusion

Melatonin has not been discredited — but the way most melatonin products are sold has been. The problems are concrete: 88% of tested gummies were inaccurately labelled, most OTC doses are 5–10 times the physiologically effective amount, and standard tablet bioavailability wastes most of what you take. Addressing those three problems — accurate labelling, low dose, high absorption — is what separates a supplement that works from one that contributes to the safety concerns making headlines. If you're reconsidering melatonin because of what you've read, the answer isn't to stop — it's to switch to a format and dose the evidence actually supports. Try BioAbsorb Liposomal Liquid Melatonin and experience what precision dosing actually feels like.

Research References

1. Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. JAMA (Journal of the American Medical Association), Vol. 329, No. 16 (2023). Found that 22 of 25 melatonin gummy products (88%) were inaccurately labelled, with melatonin content ranging from 74% to 347% of the declared quantity; one product contained no detectable melatonin.
2. Emergency Department Visits for Unsupervised Pediatric Melatonin Ingestion — United States, 2019–2022. Morbidity and Mortality Weekly Report (MMWR), Vol. 73, No. 9 (2024). CDC surveillance data estimating approximately 11,000 pediatric ED visits for unsupervised melatonin ingestion 2019–2022, with many incidents involving flavoured gummy formulations and a 530% increase in poison centre calls for pediatric melatonin exposure during 2012–2021.
3. Trends in Use of Melatonin Supplements Among US Adults, 1999–2018. JAMA, Vol. 327, No. 5 (2022). Mayo Clinic–led NHANES analysis of 55,000+ adults finding melatonin use quintupled from 0.4% to 2.1%; high-dose use (>5mg/day) more than tripled from 2005 to 2018.
4. Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders. PLOS ONE, Vol. 8, No. 5 (2013). Analysis of 19 RCTs involving 1,683 participants confirming melatonin reduced sleep onset latency by 7.06 minutes and increased total sleep time by 8.25 minutes vs. placebo; effects did not dissipate with continued use.
5. Optimizing the Time and Dose of Melatonin as a Sleep-Promoting Drug: A Systematic Review and Dose-Response Meta-Analysis. Journal of Pineal Research, Vol. 76 (2024). Analysis of 26 RCTs (1,689 observations) finding efficacy peaks at approximately 4mg/day and that administration 2–3 hours before bedtime significantly outperforms the standard 30-minute advice.
6. Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults. Clinical Interventions in Aging, Vol. 18 (2023). Narrative review finding minor adverse effects in RCTs (daytime sleepiness 1.66%, headache 0.74%) and confirming melatonin does not cause physical dependence; notes absence of long-term safety evidence beyond 12 weeks.
7. Comparative Study to Determine the Optimal Melatonin Dosage Form for the Alleviation of Jet Lag. Chronobiology International, Vol. 15, No. 6 (1998). Double-blind RCT of 320 volunteers finding that 0.5mg fast-release melatonin was almost as effective as 5mg for jet lag; supports low-dose, fast-release approach.
8. Melatonin: What You Need to Know. National Center for Complementary and Integrative Health (NCCIH), National Institutes of Health (2024). Authoritative NIH consumer summary of melatonin evidence, safety status, labelling concerns, and pediatric guidance.
9. Melatonin Dosage: How Much Should You Take?. Sleep Foundation (2025). Evidence-based dosage guidance recommending 0.5–1mg starting dose; notes dosages above 5mg provide no additional benefit and that body natural production is only 0.1–0.9mg/day.
10. Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content. Journal of Clinical Sleep Medicine, Vol. 13, No. 2 (2017). Canadian study of 16 melatonin brands finding actual melatonin content ranged from 17% to 478% of the labelled quantity across liquids, capsules, tablets, and gummies, with the greatest deviation in chewable formats.

About the Author

David Kimbell is a health writer, digital entrepreneur and former aerospace engineer, based in Ottawa, Canada. He loves translating complex science into clear, actionable guidance for consumers seeking evidence-based solutions.

---

Important Disclaimers

Medical Disclaimer: This article provides educational information only and is not intended as medical advice. Always consult with a qualified healthcare provider before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

FDA/Health Canada Statement: These statements have not been evaluated by the Food and Drug Administration or Health Canada. This product is not intended to diagnose, treat, cure, or prevent any disease.